State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Morgan Stanley Downgrades Zentalis Pharmaceuticals(ZNTL.US) to Hold Rating, Cuts Target Price to $8
Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical Milestones
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Top Midday Gainers
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $20
Market-Moving News for September 16th
Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies
Zentalis Pharmaceuticals Advances With FDA Approval and Upcoming Data
Express News | Zentalis Pharmaceuticals Inc - on Track to Meet 2024 Data Guidance
Express News | Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
Express News | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
Zentalis Pharmaceuticals Price Target Announced at $4.00/Share by Wedbush
Express News | Zentalis Pharmaceuticals Inc : Stifel Cuts Target Price to $9 From $10